XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Research Collaboration and Exclusive License Agreement - Additional Information (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Target
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]      
Deferred revenue current $ 4,935   $ 5,406
Accounts receivable outstanding $ 750   $ 0
Merck Agreement      
Research And Development Arrangement Contract To Perform For Others [Line Items]      
Number of collaboration targets | Target 2    
Non-refundable and non-creditable upfront fee $ 8,000    
Payable upon selection of second collaboration target 8,000    
Milestone payments 285,000    
Revenue recognized 2,000 $ 1,600  
Deferred revenue 6,300    
Deferred revenue current 4,900    
Merck Agreement | Maximum      
Research And Development Arrangement Contract To Perform For Others [Line Items]      
Milestone payments per collaboration target 142,500    
Milestone payments upon successful completion of certain commercial milestones $ 350,000